NASDAQ$LIDR
AEye Inc · Q1 2025 earnings
Q1 2025 earnings ·
Briefing
AEye reported Q1 2025 revenue of $64.0K, a net loss of $8.0M, diluted EPS of $-0.46.
For Q1 2025, AEye reported Revenue was $64.0K, net loss was $8.0M, diluted EPS was $-0.46. Management discusses operating trends, liquidity, and outlook in the quarterly filing.
- Revenue $64.0K for Q1 2025.
- Net loss $8.0M.
- Diluted EPS $-0.46.
Headline financials
Revenue & EPS history
AEye Inc · Revenue · Quarterly
$64K
Forward guidance
Biotech outlook emphasizes collaboration milestones, R&D spend, and cash runway.
Tailwinds
- Partnership revenue and milestone potential.
- Clinical progress on lead degraders or immuno-oncology assets.
Headwinds
- Operating losses and dilution risk.
- Trial and regulatory execution uncertainty.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q1 2025
-0.4%
Avg return
Earnings day
-1.1%
Avg return
5 days after
-9.9%
Avg return
30 days after
47%
7 / 15 earnings
Positive
+18.1%
Q4 2025
Best reaction
-15.1%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -15.1% | -26.9% | -34.7% | |
| Q4 2025 | +18.1% | +44.5% | +14.2% | |
| Q3 2025 | +3.4% | +6.9% | +13.8% | |
| Q2 2025 | -1.4% | -3.9% | -1.1% | |
| Q1 2025 | +8.0% | +22.1% | +36.7% | |
| Q3 2024 | -5.3% | -15.8% | -1.3% | |
| Q2 2024 | -3.2% | -12.0% | -13.6% | |
| Q1 2024 | -1.2% | -2.0% | -7.6% | |
| Q3 2023 | -5.6% | -5.1% | -35.0% | |
| Q2 2023 | -13.3% | -33.3% | -45.6% | |
| Q1 2023 | +2.5% | -1.5% | -7.4% | |
| Q3 2022 | +3.3% | +26.3% | +23.0% | |
| Q2 2022 | +0.4% | -22.0% | -42.8% | |
| Q1 2022 | +14.4% | +26.3% | -30.2% | |
| Q3 2021 | -11.2% | -20.7% | -17.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro